News | August 25, 2021
Cipla forms JV with Kemwell Biopharma
The agreement is to develop, manufacture and commercialise biosimilars for the global market.
The agreement is to develop, manufacture and commercialise biosimilars for the global market.
_256_384.jpg)
In FY21, the company reported a net profit of Rs 419 crores compared to Rs 101 crores in FY 20 and consolidated total income at Rs 6092 crores, up 19% Y-o-Y
It is the only biopharmaceutical company in India to offer all three dosage strengths of the drug (125mcg, 250mcg, and 500mcg)
It’s an AB-rated generic therapeutic version of Durezol
OptumRx to make Pear’s three commercial Prescription Digital Therapeutics accessible to patients with Optum formulary access.
Filing for WHO Emergency Use Authorisation this month
India business contributes to a stellar performance
MitraClip implants give a new lease of life for frail and elderly patients who cannot go in for conventional open-heart surgery
It had an estimated market size of US $ 32 million as of June 2021
Total income grew in the quarter
Subscribe To Our Newsletter & Stay Updated
